MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Investment analysts at Wedbush issued their Q3 2024 earnings per share estimates for shares of MoonLake Immunotherapeutics in a research note issued to investors on Monday, November 4th. Wedbush analyst Y. Zhong anticipates that the company will earn ($0.35) per share for the quarter. Wedbush has a "Strong-Buy" rating on the stock. The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.54) per share. Wedbush also issued estimates for MoonLake Immunotherapeutics' Q4 2024 earnings at ($0.38) EPS, FY2024 earnings at ($1.33) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.82) EPS, FY2027 earnings at ($1.59) EPS and FY2028 earnings at $0.38 EPS.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.11). During the same quarter last year, the firm posted ($0.23) earnings per share.
A number of other equities analysts have also issued reports on the company. Wolfe Research lowered MoonLake Immunotherapeutics from an "outperform" rating to a "peer perform" rating in a research report on Monday, August 26th. Needham & Company LLC reissued a "buy" rating and issued a $62.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, September 12th. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, October 15th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of MoonLake Immunotherapeutics in a research note on Monday, September 23rd. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $78.73.
Get Our Latest Report on MLTX
MoonLake Immunotherapeutics Trading Down 1.6 %
MLTX stock traded down $0.81 during trading on Thursday, reaching $50.67. The stock had a trading volume of 248,086 shares, compared to its average volume of 378,216. The firm has a fifty day moving average price of $49.19 and a 200 day moving average price of $45.28. The company has a market capitalization of $3.24 billion, a P/E ratio of -56.38 and a beta of 1.28. MoonLake Immunotherapeutics has a 1-year low of $35.53 and a 1-year high of $64.98.
Insider Activity
In related news, Director Simon Sturge sold 171,000 shares of the stock in a transaction on Friday, October 4th. The stock was sold at an average price of $53.72, for a total value of $9,186,120.00. Following the completion of the transaction, the director now owns 171,980 shares in the company, valued at $9,238,765.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 12.02% of the company's stock.
Institutional Investors Weigh In On MoonLake Immunotherapeutics
Several institutional investors have recently made changes to their positions in MLTX. GSA Capital Partners LLP increased its stake in shares of MoonLake Immunotherapeutics by 1.9% during the 3rd quarter. GSA Capital Partners LLP now owns 22,127 shares of the company's stock worth $1,116,000 after purchasing an additional 403 shares during the last quarter. California State Teachers Retirement System increased its holdings in shares of MoonLake Immunotherapeutics by 2.7% during the 1st quarter. California State Teachers Retirement System now owns 16,366 shares of the company's stock valued at $822,000 after acquiring an additional 429 shares during the last quarter. US Bancorp DE bought a new position in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $44,000. DNB Asset Management AS lifted its holdings in MoonLake Immunotherapeutics by 29.8% in the 2nd quarter. DNB Asset Management AS now owns 7,372 shares of the company's stock worth $324,000 after purchasing an additional 1,694 shares during the last quarter. Finally, Quarry LP boosted its position in MoonLake Immunotherapeutics by 172.7% during the second quarter. Quarry LP now owns 3,000 shares of the company's stock worth $132,000 after purchasing an additional 1,900 shares during the period. 93.85% of the stock is currently owned by institutional investors and hedge funds.
About MoonLake Immunotherapeutics
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Read More
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
